Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patients

INTRODUCTION: A new dosing schedule for the oncology immunotherapy pembrolizumab, every 6 weeks (Q6W), has been approved by the U.S. FDA, reducing the frequency of visits to infusion centers. We quantified the time spent by oncologists, nurses, patients, and caregivers per melanoma-related immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguiar-Ibáñez, Raquel, Scherrer, Emilie, Grebennik, Dmitri, Cook, John, Bagga, Shalini, Sawhney, Baanie, Khandelwal, Anvi, Soefje, Scott A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910242/
https://www.ncbi.nlm.nih.gov/pubmed/36759810
http://dx.doi.org/10.1186/s12913-022-08904-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910242/
https://www.ncbi.nlm.nih.gov/pubmed/36759810
http://dx.doi.org/10.1186/s12913-022-08904-4

Ejemplares similares